Health care stocks were softer Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.4%.
The iShares Biotechnology ETF (IBB) rose 0.5%.
In corporate news, Merck (MRK) issued a downbeat full-year outlook, overshadowing stronger-than-expected Q4 results. The shares fell past 10%.
Pfizer's (PFE) Q4 results topped market expectations amid double-digit revenue growth across key segments, while the pharmaceutical giant reiterated its full-year outlook. Its shares were down 1.7%.
Novartis (NVS) is on the hunt for next-generation obesity drug candidates, despite its main focus remaining on therapeutic areas where it has an established presence, The Wall Street Journal reported Tuesday, citing an interview with Chief Executive Vasant Narasimhan. Novartis shares were fractionally lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.